The FTO inhibitor Rhein is a promising option for the treatment of multidrug resistance AML

Shuling Zhang(Lanzhou University), Li Zhao(First Hospital of Lanzhou University), Lili Tao(Vanderbilt University Medical Center), Jincai Yang(First Hospital of Lanzhou University), Lanxia Zhou, Youfan Feng(Lanzhou University), Juan Cheng(Northwestern University), Jianle Lu(Lanzhou University)

Research Square

January 3, 2024

10.21203/rs.3.rs-3813501/v1

Cited by 0

Related Papers

Association analyses identify six new psoriasis susceptibility loci in the Chinese population

|Nature Genetics|2010|317

Acute myeloid leukemia (<scp>AML)</scp>‐derived mesenchymal stem cells induce chemoresistance and epithelial–mesenchymal transition‐like program in <scp>AML</scp> through <scp>IL</scp>‐6/<scp>JAK2</scp>/<scp>STAT3</scp> signaling

|Cancer Science|2023|46

Expression of estrogen receptor $beta; in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis

|FEBS Letters|2004|20

PLCB4 upregulation is associated with unfavorable prognosis in pediatric acute myeloid leukemia

|Oncology Letters|2019|13

Rhein exerts anti-multidrug resistance in acute myeloid leukemia via targeting FTO to inhibit AKT/mTOR

|Anti-Cancer Drugs|2024|10